Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Hershey Co (HSY) Price & Performance

AbCellera Biologics IncTrade
Hershey CoTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Hershey Co — how do they compare? AbCellera Biologics Inc trades at $10.04 (market cap $2.99B), while Hershey Co trades at $182.34 (market cap $36.56B). The key difference: Hershey Co is far larger — about 12.2× AbCellera Biologics Inc's market cap, and Hershey Co pays a 3.19% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLHSY
Market Cap
$2.99B$36.56B
Sector
HealthConsumer Staples
52-Week High
$9.76$236.28
52-Week Low
$2.78$162.31
Enterprise Value
$2.58B$41.70B
Dividend Yield
3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

Hershey Co

Hershey (HSY) trades at $182.75, up 0.22% with a bullish technical signal and strong fundamental momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth trends upward to $11.69 billion in 2025. Analyst consensus targets $196.78 with 69% hold ratings, reflecting cautious optimism amid margin recovery from favorable cocoa contracts and dividend growth.

The outlook remains positive with earnings rebound and pricing power, though risks include volume declines and competitive pressures. Current valuation at 24.86 P/E appears reasonable given 32.81% ROE and improving cash flow trends. Institutional sentiment is mixed with recent insider sales offset by upward guidance revisions.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Hershey Co

Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.

Read more on HSY